Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | MLYCD | O95822 | 1/20 | 0.37 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.36 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.36 |
| ▸ | SOD1 | P00441 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 4/20 | 0.36 |
| ▸ | ACP3 | P15309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6211647 | 0.88 | RXRA (0.41) | IDO1DAOTAAR1RXRARXRB | |
| SCHEMBL16956811 | 0.86 | P2RX1 (0.38) | IDO1TAAR1P2RX1TMPRSS4TACR1 | |
| SCHEMBL5540305 | 0.82 | IDO1 (0.47) | IDO1CES2DAOTAAR1RXRA | |
| SCHEMBL1758495 | 0.79 | TAAR1 (0.59) | IDO1DAOTAAR1ACP3 | |
| SCHEMBL1838110 | 0.78 | DAO (0.45) | IDO1CES2DAOTAAR1RXRA | |
| SCHEMBL3246600 | 0.77 | TAAR1 (0.54) | IDO1CES2DAOTAAR1 | |
| SCHEMBL624792 | 0.77 | IDO1 (0.47) | IDO1CES2DAOTAAR1RXRA | |
| SCHEMBL1776129 | 0.73 | IDO1 (0.52) | IDO1CES2DAOTAAR1RXRA | |
| SCHEMBL5541662 | 0.72 | DAO (0.41) | IDO1CES2DAOTACR1 | |
| SCHEMBL2096262 | 0.72 | IDO1 (0.57) | IDO1CES2DAOMTORMLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5872262-A | COMPOUNDS AS INHIBITORS OF PLASMEPSIN AND CATHEPSIN | PHARMACOPEIA, INC. (US) | 1999-02-16 | — | — | US | claimed |
| US-5734054-A | Hydroxy-amino acid amides | PHARMACOPEIA, INC. (US) | 1998-03-31 | — | — | US | claimed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1723199-A | 1,4-disubstituted piperidine derivatives and their use as 11-beta hsd1 inhibitors | ASTRAZENECA AB (SE) | 2006-01-18 | — | — | CN | disclosed |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1556349-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | Astrazeneca AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| CN-1515259-A | 4-aminosubstituted-2-substituted-1,2,3,4-tetrahydroquinoline used as CETP inhibitor | �������Զ�˹�Ʒ� | 2004-07-28 | — | — | CN | disclosed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | disclosed |
| US-5892038-A | ENZYME INHIBITORS FOR TREATMENT OF DISEASES SUCH AS MALARIA | PHARMACOPEIA, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| US-5872262-A | COMPOUNDS AS INHIBITORS OF PLASMEPSIN AND CATHEPSIN | PHARMACOPEIA, INC. (US) | 1999-02-16 | — | — | US | disclosed |
| US-5734054-A | Hydroxy-amino acid amides | PHARMACOPEIA, INC. (US) | 1998-03-31 | — | — | US | disclosed |
| WO-1995011895-A1 | N-BENZOYL-4-OXY/THIO-2-SUBSTITUTED PIPERIDINES AS SUBSTANCE-P RECEPTOR ANTAGONISTS | CIBA-GEIGY AG (CH) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | IDO1 3181/4885CES2 3025/4885DAO 1115/4885 |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | HSD11B1, HSD3B1, P4HA1 | IDO1 749/4885CES2 419/4885DAO 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.